May 4, 2018, Reno, NV. Expanded Go-To-Market Team

May 4, 2018, Reno, NV. Expanded Go-To-Market Team

Cyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer, R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan. Jim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses medical product management experience as well. We are confident her leadership will bring added perspective to a product targeted for the female population.” Matt Benardis, CEO, added “We have already seen results from her leadership of the recent kick-off meeting with the comprehensive Go-To- Market team and her engagement of each department regarding oversight, organization and accountability.” Please see the attached Team photo from a very successful kick-off. Marly brings over 30 years of healthcare and corporate operations depth, as well as consulting and management experience to our team. Her career also includes experience as a pediatrics and specialty care nursery nurse. Consulting lessons learned include experience in Healthcare, Big Four, Fortune 500 professional services and software environments, plus co-founding and managing a boutique management consulting business for over 10 years. Ms. Heidkamp’s operations experience in healthcare and software environments include leadership roles in electronic health records software, healthcare consulting, hospital-wide training and education, vendor credentialing program and software for hospitals, hospital business transformation, strategic planning and execution and customer loyalty programs. Her educational background includes Masters of Science in Adult Learning, with emphasis in Organizational Development, Instructional Design and Change Management (Northern Illinois University in DeKalb, IL), Bachelor of Science in Nursing (Benedictine University, Lisle, IL) and Certificate in Leading People, Leading Organizations (USC Marshall School of Business). Please join us in...

April 30, 2018, Reno, NV. Clinical Trial Resumption Update

As Cyrcadia prepares to move to clinical markets, Matt Benardis, CEO; Jim Holmes, CFO; along with our Clinical Research associate (CRA) met with clinical trial investigators and administration at El Camino Hospital, in San Mateo, CA, to discuss previous participant follow-up and trial resumption with our modified clinical product and associated study protocol. Do note trial details are not revealed in advance nor can Cyrcadia, Inc., the study Sponsor, have any impact on the procedures in order to maintain FDA trial integrity. However, they did ascertain a number of positive aspects with El Camino trial manager Initial trial participant follow-up continues to contribute to the Artificial Intelligence analytics improvement and population of the database. Trial managers confirmed their agreement and enthusiasm for protocol revisions regarding the reduction of wear time for trail participants to 2 hours, potentially accelerating participant subscription. Trial managers were very positive and affirmed their ongoing interest in the resumption of the study and its completion providing study outcome data for FDA disclosure. It is important to understand one of our issues was women recently diagnosed with breast cancer were reluctant to be committed to an up to 24-hour wear time. All agreed that our revised 2-hour wear time protocol would potentially increase participation and accelerate trial completion. It is notable that our artificial intelligence algorithm research has developed verifiable evidence to substantiate a 2-hour wear time with equivalent accuracy results as compared to the historical 24-hour wear time. Next steps Updated production schedule from Jabil Electronics and Cyrcadia Asia to provide product revisions related to shelf life and improved ease of use, as well as...

Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter

February 27, 2018 Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations. License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules). Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year. Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery. Status of Product Development and Manufacturing Under CA’s...

Cyrcadia, Inc. Wins Prestigious Cannes Lions Awards

Cyrcadia, Inc. (CI) announced it has won two prestigious awards at the Cannes Lions International Festival of Creativity, a global event for the creative communications, marketing and advertising world. Held in Cannes, France and attended by over 10,000 delegates, Lion awards are considered the most coveted in the industry. The first award was a Bronze Lion in the category of Innovation, which honors ground-breaking technology and problem-solving. It specifically looks at how technology, data and ideas, when working in unison, can revolutionize lives. Cyrcadia shared the Bronze award with industry giants such as Google, Shell and Apple. The second award was a Silver Glass Lion award, recognizing ideas that could change the world and positively impact gender inequality or injustice. Cyrcadia’s ability to deliver early breast cancer health monitoring to the mass populations of women who have little or no access to quality health care was key to Cyrcadia’s award achievement. Cyrcadia is developing and marketing a device and software that monitors for biometric changes that correlate to breast cancer . Known as the iTBra, the device is based on wearable sensor patches that are placed under a woman’s own garments and worn for two hours. The sensor data results processed through Cyrcadia’s artificial intelligence (AI) lab can be automatically communicated to the patient, her physician and insurance company. Based on Cyrcadia’s monitoring device, a patient will be recommended for further investigation by a physician. The company’s technology has obtained U.S. FDA 510(k) Class II clearance. While the technology is based on historic data from a trial of 200 patients, recent validation trials on 46 patients have confirmed prior...

Lifeline announces transfer of breast cancer detection technology to subsidiary

Reno-based Lifeline Biotechnologies, Inc. (OTC PINK: LLBO) recently transferred breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 shares of Cyrcadia, Inc. common stock and a $110,000 cash and $220,000 promissory note. The additional 4,670,000 shares added to Lifeline’s original 8,000,000 shares totals 12,670,000 shares. Lifeline’s ownership is increased to over 45 percent of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.’s largest single shareholder. The technology transfer enabled Cyrcadia, Inc. to license Cyrcadia Asia Limited for the marketing of Cyrcadia, Inc. products throughout the Asian markets. Rob Royea, Cyrcadia, Inc.’s former CEO, is moving to Hong Kong to manage the Asian opportunity, representing a population of 1.8 billion people. Cyrcadia, Inc. received the following compensation for the license to Cyrcadia Asia Limited: An $830,000 Cyrcadia, Inc. equity investment at $1.00 per share with an equal $1.00 warrant; a $1,050,000 promissory note; Cyrcadia Asia, Limited assumed approximately $3,000,000 in product development costs for the Bluetooth and added sensor costs. Cyrcadia, Inc. received an equity interest in Cyrcadia Asia, Limited. Additionally, Cyrcadia Asia Limited assumed approximately $500,000 of Cyracdia, Inc.’s annual general and administrative expenses. Cyrcadia Asia Limited will license Cyrcadia, Inc. for the developed Bluetooth and additional sensors products once development is completed. The transaction is valued at approximately $5 million. The Bluetooth capabilities will enable patient data to be transmitted directly, over the Internet, to the testing physician, and/or the data interpretation center. The added sensors will enable the systems to exactly locate the tissue abnormality or cancer within the breast tissue. By locating the abnormality, the physician performing the biopsy will know exactly where the probe should be inserted into the tissue. Cyrcadia, Inc., a Nevada corporation, founded by...